{"disease":{"id":"infective-otitis-media","name":"Infective otitis media","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":45,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"azithromycin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zithromax","generic_name":"azithromycin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor","drug_class":"Macrolide antibiotic (azalide)","quality_score":67,"revenue":"399","mechanism":"Macrolide antibiotic that binds the 50S ribosomal subunit, inhibiting bacterial protein synthesis with an exceptionally long tissue half-life."},{"drug_id":"cefradine","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefradex","generic_name":"cefradine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"cefradine","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"amoxycillin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxycillin","company_name":"King George's Medical University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"benzylpenicillin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Penicillin G Potassium In Plastic Container","generic_name":"Benzylpenicillin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"sulfamethoxazole","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azo Gantanol","generic_name":"SULFAMETHOXAZOLE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Sulfonamide Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ampicillin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"sulfafurazole","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azo Gantrisin","generic_name":"sulfafurazole","company_name":"Alra","drug_phase":"marketed","molecular_target":"Endothelin-1 receptor","drug_class":"Sulfonamide Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"trimethoprim","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trimethoprim","generic_name":"TRIMETHOPRIM","company_name":"Dr Reddys Labs Sa","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"Sulfonamide Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefaclor","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceclor","generic_name":"CEFACLOR","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"cefaclor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"cefuroxime-axetil","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceftin","generic_name":"CEFUROXIME AXETIL","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":50,"revenue":null,"mechanism":"Ceftin works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"demeclocycline","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Demethylchlortetracycline","generic_name":"DEMECLOCYCLINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor beta","drug_class":"Tetracycline-class Antimicrobial","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"sulfamethizole","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulfurine","generic_name":"SULFAMETHIZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"sulfamethizole","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"amoxicillin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amoxil","generic_name":"amoxicillin","company_name":"Generic (originally Beecham/GSK)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"Aminopenicillin (Beta-lactam antibiotic)","quality_score":56,"revenue":null,"mechanism":"Broad-spectrum aminopenicillin that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins."},{"drug_id":"erythromycin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"E-Mycin","generic_name":"erythromycin","company_name":"Generic (originally Abbott/Lilly)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1","drug_class":"Macrolide [EPC]","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"cefprozil","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefzil","generic_name":"cefprozil","company_name":"Teva Pharmaceuticals USA","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial [EPC]","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"meclocycline","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meclan","generic_name":"MECLOCYCLINE","company_name":"Johnson And Johnson","drug_phase":"marketed","molecular_target":"","drug_class":"meclocycline","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"cyclacillin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ciclacillin","generic_name":"CYCLACILLIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"cyclacillin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bacampicillin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carampicillin","generic_name":"BACAMPICILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"bacampicillin","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"phenazone","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azophen","generic_name":"phenazone","company_name":"","drug_phase":"marketed","molecular_target":"Nicotinate phosphoribosyltransferase","drug_class":"phenazone","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"garenoxacin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Geninax","generic_name":"GARENOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"garenoxacin","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxon","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"erythrocin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzamycin","generic_name":"Erythromycin Lactobionate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Macrolide","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ceftibuten","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cedax","generic_name":"ceftibuten","company_name":"Burke Therap","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefdinir","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Omnicef","generic_name":"CEFDINIR","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefpodoxime-proxetil","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantin","generic_name":"CEFPODOXIME PROXETIL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefalexin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keflex","generic_name":"cefalexin","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"Solute carrier family 15 member 2","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefuroxime","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinacef","generic_name":"CEFUROXIME","company_name":"GSK","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Cephalosporin Antibacterial","quality_score":65,"revenue":null,"mechanism":"Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"clavulanic-acid","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Augmentin 250","generic_name":"CLAVULANIC ACID","company_name":"Dr Reddys Labs Inc","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"minocycline","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Minocycline Hydrochloride","generic_name":"MINOCYCLINE","company_name":"Rempex","drug_phase":"marketed","molecular_target":"","drug_class":"Tetracycline-class Drug","quality_score":75,"revenue":null,"mechanism":"MINOCYCLINE works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"ciprofloxacin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"clarithromycin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Biaxin","generic_name":"clarithromycin","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Macrolide Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":"Clarithromycin is a macrolide antimicrobial drug."},{"drug_id":"cefixime","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Suprax","generic_name":"CEFIXIME","company_name":"","drug_phase":"marketed","molecular_target":"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1","drug_class":"cefixime","quality_score":10,"revenue":null,"mechanism":"Suprax works by inhibiting the bacterial enzyme 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1, disrupting bacterial cell wall synthesis."},{"drug_id":"ceftriaxone","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"cephradin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cephradin","company_name":"Sohag University","drug_phase":"phase_2","molecular_target":"Matrix metalloproteinase-9, Somatostatin receptor type 4, Bacterial penicillin-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"penicillin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"penicillin","company_name":"Karlstad University","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amoxicilli","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxicilli","company_name":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phenoxymethylpenicillin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Phenoxymethylpenicillin","company_name":"Katarina Hedin","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Penicillin-binding protein 1A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fusidic-acid","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"minocyclin","indication_name":"Infective otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Minocyclin","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":45,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}